Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPI-SK17
- Development stage
- Unknown
- Lead developer
- EpiPharm
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
EPI-SK17 is a proprietary topical small molecule therapy being developed by EpiPharm for the treatment of seborrheic keratosis (SK). It is designed as a first-in-class treatment that works by inducing selective apoptosis in the keratinocytes that make up SK lesions. This mechanism allows for the non-invasive clearance of the growths, offering a potential alternative to physical destruction methods such as cryotherapy, curettage, or laser therapy, which can be associated with pain, pigmentary changes, and scarring. As of early 2024, EPI-SK17 has completed a Phase 2a dose-ranging study and is preparing to enter Phase 2b clinical trials.
Beyond the preview
Go deeper on EPI-SK17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPI-SK17.